Home › Compound Library › Insulin Regular (Humulin R)

Insulin Regular (Humulin R)

Hormoneprescriptionsubcutaneous · inferred

Short-acting recombinant human insulin identical in sequence to endogenous insulin. Forms zinc-stabilized hexamers at injection-site concentration; dissociation to dimers/monomers is rate-limiting for absorption. Onset 30-60 min, peak 2-4h, duration 6-8h. Can be given SC or IV (only insulin formulation suitable for IV use).

Projected serum levels — 10 units (≈ 0.35 mg), once daily

Insulin Regular (Humulin R)
Insulin Regular (Humulin R) modeled serum levels, 10 units (≈ 0.35 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 10 units (≈ 0.35 mg) once daily (subcutaneous).

Modeled steady state after ~1 days: peak ≈ 0.17 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormone
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
2.5 h
Common dose
10 units (≈ 0.35 mg)
Suggested maximum
100 units/day
Reference dose range
5–100 units (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Insulin Aspart (NovoLog) + Insulin Regular (Humulin R) Stacked effects

    Insulin Aspart (NovoLog) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Glargine (Lantus) + Insulin Regular (Humulin R) Stacked effects

    Insulin Glargine (Lantus) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin Lispro (Humalog) + Insulin Regular (Humulin R) Stacked effects

    Insulin Lispro (Humalog) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

  • moderate
    Insulin NPH (Humulin N) + Insulin Regular (Humulin R) Stacked effects

    Insulin NPH (Humulin N) and Insulin Regular (Humulin R) both push the igf1 receptor and insulin receptor in the same direction.

Serum checks 4 modeled interaction pairings for insulin regular (humulin r) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus (DCCT) The Diabetes Control and Complications Trial Research Group · New England Journal of Medicine, 1993 DOI

    Landmark 1,441-patient trial proving intensive insulin therapy (using regular insulin plus NPH or pump) reduced retinopathy by 76%, nephropathy by 50%, and neuropathy by 60% vs conventional therapy in type 1 diabetes,…

  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group · The Lancet, 1998 DOI

    Definitive 3,867-patient trial establishing that intensive glucose control with insulin or sulfonylureas reduced microvascular complications by 25% in type 2 diabetes, with regular insulin used as the primary insulin…

  3. Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro Lepore M et al. · Diabetes, 2000 DOI

    Comprehensive PK/PD comparison of four insulin formulations, quantifying that regular insulin (IV reference) has a metabolic clearance half-life of ~5 min, while SC formulations exhibit absorption-limited kinetics that…

3 published studies referenced in the app, each with a plain-language summary.